News & Updates

Show Multimedia Only

GLP-1 receptor agonist use poses no risk of suicidality, self-harm

13 Sep 2024

Users of glucagon-like peptide-1 (GLP-1) receptor agonists, most of whom have type 2 diabetes, are not at increased risk of suicide death, self-harm, or incident depression and anxiety-related disorders, as shown in a study.

GLP-1 receptor agonist use poses no risk of suicidality, self-harm

13 Sep 2024

$Anti-TNFα agents safe, effective in steroid-refractory microscopic colitis$

Anti-TNFα agents safe, effective in steroid-refractory microscopic colitis

13 Sep 2024

Treatment with vedolizumab and antitumour necrosis factor-α agents provides clinical benefits, with an acceptable safety profile, in patients with steroid-refractory microscopic colitis (MC), suggests a study.

Anti-TNFα agents safe, effective in steroid-refractory microscopic colitis

13 Sep 2024

Rezum boosts sexual function in men with or without ED

13 Sep 2024

Treatment with Rezum improves sexual function in men with baseline erectile dysfunction (ED) and maintains long-term sexual function in those without ED, reports a study. However, men with ED may go through temporary decline in sexual function at 1 year.

Rezum boosts sexual function in men with or without ED

13 Sep 2024

Brivaracetam benefits Asian adults with uncontrolled focal-onset seizures

13 Sep 2024 by

Adjunctive brivaracetam (BRV) reduces seizure frequency and improves response in Asian adults with uncontrolled focal-onset seizures (FOS), findings from the phase III therapeutic confirmatory EP0083 study suggest.

Brivaracetam benefits Asian adults with uncontrolled focal-onset seizures

13 Sep 2024

Fewer CV events after COVID-19 vaccine-related myocarditis

13 Sep 2024 by

In a nationwide French cohort study, myocarditis attributed to COVID-19 mRNA vaccination causes fewer cardiovascular (CV) events at 18 months of follow-up than that attributed to SARS-CoV-2 infection or myocarditis of conventional aetiologies.

Fewer CV events after COVID-19 vaccine-related myocarditis

13 Sep 2024

Zasocitinib shows promise as psoriasis treatment

13 Sep 2024

In the treatment of psoriasis, selective inhibition of tyrosine kinase 2 (TYK2) with zasocitinib appears to have superior effects compared with placebo, with greater skin clearance observed over 12 weeks, according to data from a phase 2b study.